Clinical Trials
81 trialsEVAX
University Hospital, Bordeaux
SLM + Axitinib for Clear Cell RCC
University of Iowa
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Grupo Espanol de Tumores Neuroendocrinos
AXMUS-C
Imperial College London
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
M.D. Anderson Cancer Center
KEYNOTE-426
Merck Sharp & Dohme LLC
AXAGIST
Maria Sklodowska-Curie National Research Institute of Oncology
JAVELIN Renal 101
Pfizer
ALARICE
The University of Hong Kong
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
Memorial Sloan Kettering Cancer Center
AXIPAN
Assistance Publique - Hôpitaux de Paris
NPC - AXEL Study : Axitinib-Avelumab
Chinese University of Hong Kong
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
Lynkcell Europe
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
Pfizer
A-PREDICT
Institute of Cancer Research, United Kingdom
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Astellas Pharma Inc
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
M.D. Anderson Cancer Center
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
X4 Pharmaceuticals
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
University of Miami
PIVOT IO 011
Bristol-Myers Squibb
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
City of Hope Medical Center
AXIPAP
Centre Leon Berard
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
Pfizer
JAVELIN Renal 100
Pfizer
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
NYU Langone Health
Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Pfizer
NAXIVA
Scottish Clinical Trials Research Unit
Expansion Trial for Axitinib In Head And Neck Cancer
University of Michigan Rogel Cancer Center
Axi-STS
Sheffield Teaching Hospitals NHS Foundation Trust
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
University of California, Irvine
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
National Institutes of Health Clinical Center (CC)
A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
Seoul National University Hospital
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Pfizer
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
Pfizer
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
AXITINIB
University Health Network, Toronto
Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies
University of Wisconsin, Madison
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
University of Wisconsin, Madison
FavorAx
Kidney Cancer Research Bureau
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
SCRI Development Innovations, LLC
SGC-AX14
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
Pfizer
AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
Pfizer
AxiGII
Universitair Ziekenhuis Brussel
GliAvAx
Universitair Ziekenhuis Brussel
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Pfizer
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
Pfizer